The full original versions of the articles in Vigilance News are available in English as ePapers or PDFs. In addition, we are providing a summary of these articles in four languages as a quick source of information.
Summaries:
Intravenous immunoglobulins (IVIg) are widely used for immunoglobulin replacement therapy in patients with antibody deficiencies and for various immunomodulatory indications. As IVIg preparations are derived from pooled plasma from healthy donors, a broad spectrum of polyclonal IgG antibodies may be passively transferred to recipients.
We report on the case of a 54-year-old woman with plasma cell myeloma and hypogammaglobulinaemia who developed newly detectable hepatitis B surface (anti-HBs) and total hepatitis B core (anti-HBc) antibodies two days after the second IVIg administration. Serological testing prior to treatment had been negative for hepatitis B surface antigen (HBsAg), anti-HBs and anti-HBc antibodies. At the time of anti-HBs/anti-HBc positivity, HBsAg remained negative. Further evaluation with hepatitis B virus (HBV) DNA testing by polymerase chain reaction (PCR) showed no detectable viral load, and liver function tests remained within the normal range, arguing against an active infection.
Given the close temporal association, the biological plausibility and the absence of evidence of active infection, the newly detected antibodies were considered consistent with passive antibody transfer following IVIg administration. Passive transfer of viral antibodies following IVIg therapy may lead to misleading serological results and inappropriate clinical management. This case highlights the importance of awareness of this phenomenon and of careful interpretation of hepatitis B serology in patients receiving IVIg.
Johanna Erlwein, Mia Zahorecz
B-cell-depleting therapies targeting CD20 are widely used in haematological malignancies and autoimmune conditions. They induce peripheral B-cell depletion, which is typically reversible within six to 12 months. However, rare cases of prolonged or irreversible B-cell depletion have been reported, with potentially serious consequences. This complication remains poorly characterised, and no monitoring or clinical decision-making framework has been formally established.
We report on two patients who developed persistent complete B-cell depletion for five years or more after rituximab exposure, identified in the context of active collaboration between the oncology department and the Geneva Regional Pharmacovigilance Centre. The first patient has remained completely B-cell depleted, with secondary hypogammaglobulinaemia, for over a decade. The second patient, a 61-year-old woman with a B2 thymoma, has since exhibited persistent B-cell depletion, complicated by recurrent severe infections including septic shock.
Excerpt from the official page. The original is authoritative. Continue reading at Swissmedic ↗